We are passionate about patient quality.
Our Acting Director of Patient Care, Jane Campbell is primarily responsible for the provision of expert clinical guidance to our Trust Board and for establishing and quality assuring appropriate standards of care and clinical governance. The Director is responsible for setting the standards of clinical practice and underpinning educational and training levels required to achieve those the Trust operates to and assuring our Corporate Board of our compliance to those standards.
- the provision of strong clinical leadership at all levels throughout the Trust
To ensure the Trust has the clinical capacity to provide safe reliable care for its patients
- to establish appropriate standards of clinical care and ensure they are communicated and understood by all staff responsible for delivering care
To ensure systems are in place to monitor delivery for clinical care across all areas of Trust activity
- to contribute to the development and implementation of alternative models of clinical care to meet the diverse needs of patients
- to ensure the Trust Board understands its statutory duties in respect of patient care and takes action to ensure these duties are met
Care Quality Commision
We are regulated by the Care Quality Commission (CQC).
The Care Quality Commission website shows a summary of whether this service is meeting the essential standards of safety and quality.
If a service is meeting all standards it will show a tick; if a service is not meeting one standard or more, it will show a cross and an explanation that the CQC require improvements or are taking enforcement action.
You can see our full profile page on the CQC website at http://www.cqc.org.uk/directory/rye
The Trust is committed to minimising all risks associated with infection control and reducing the impact of healthcare associated infection on patients staff and the organisation overall. The Trust encourages the open reporting of infection incidents and risks as part of its adverse incident reporting procedures
The Infection, prevention control and decontamination policy covers all the aspects of infection control and decontamination that are required to protect all staff, patients and third parties, and those issues and procedures raised by Assurance framework or required for statutory purposes
South Central Ambulance Service NHS Foundation Trust’s SCAS Clinical strategy ‘Future opportunities’ presents our exciting vision for the services we provide and, importantly, work is already taking place to turn this vision into reality. We are driven by one overarching ambition, which is to deliver the best possible service to our patients.
Our aims are to:
- provide the best care in all our services
- provide care based on the patient’s individual needs
- make it easier, as well as quicker, to access emergency and urgent care
- to get the right balance between highly specialist care where it is needed and more local care where appropriate
- play our role in encouraging healthier communities and individuals.
The SCAS Clinical strategy ‘Future opportunities’ helps us and our teams to understand the agenda we face going forward. Quality is always going to be a key priority for our services, to deliver quality will mean us working differently – focusing on patients and their health needs, working across pathways and working with other clinical colleagues. Our staff are close to our patients, so can see how they can change things to make them better for them. We look forward to working with you to provide the safe and high quality care for our communities.
This strategy has been developed by working closely with internal colleagues and has been consulted on with key stakeholders. Their comments have been considered, and where appropriate, incorporated into the document. A common theme from discussions is that partner agencies have commented on us being involved in taking forward both short term Quality, Innovation, Productivity and Prevention projects as well as having an active part in the longer term transformational change programmes. Such work includes active participation and contribution to urgent care boards and clinician to clinician dialogue. We recognise that we have a role to play in influencing the strategy of partner organisation.
Clinical Quality Governance Strategy
The purpose of the Clinical and quality governance strategy is to establish and to provide assurance that robust systems are being embedded into the organisation to address national and local clinical and quality governance requirements. These need to continue to be progressed and are key to the transition of the Trust being a clinically led organisation over the next 2 years, and in the shorter term, over the period leading to application for Foundation Trust.
However, this is a long-term strategy and is dynamic and it will need to be reviewed bi-annually and adapted to meet future local needs of the Trust (given the changing Healthcare landscape as outlined within Liberating the NHS Equity and Excellence, DH 2010); this will in turn have an effect on the future local needs of trusts.
Annual Quality Report
The Trust Board is fully engaged with improving quality in our organisation and undertake regular leadership walkarounds. The Board will robustly monitor and scrutinise emerging risks to quality standards via the integrated performance report and measures.
Throughout the development of this report we have involved our staff and clinical teams, Health Overview and Scrutiny Committees (HOSCs), our NHS commissioners and our governors and members.
Declaration of Single Sex Accommodation
We wish to inform you that we do not have any mixed-sex accommodation within the ambulance service.
Joint Royal Colleges Ambulance Liaison Committee
The Joint Royal Colleges Ambulance Liaison Committee (JRCALC) develops national clinical practice guidelines for NHS paramedics. The Clinical Guidelines have been adopted by South Central Ambulance Service and form the basis for UK paramedic training and education. The guidelines are reviewed on a five year cycle and are developed or updated, based on systematic reviews of the evidence and consensus agreement. To access the JRCALC clinical practice guidelines click here.
Clinical research informs the guidelines and recommendations that underpin delivery of clinical care. Undertaking research is a priority for a trust constantly seeking to improve and develop patient care. Patients benefit from potentially receiving novel treatments before they become part of the recommended guidelines and staff benefit from contributing to the evidence on which new guidelines are based.
The research team in SCAS is responsible for overseeing all clinical research projects undertaken by the Trust. We are a small team, and we have been involved in large scale research trials including PARAMEDIC (the Prehospital Randomised Assessment of a Mechanical Device In Cardiac arrest). SCAS was one of four ambulance trusts which took part in this national study, which received the prestigious accolade of ‘Trial of the Year 2014’ awarded by The Society for Clinical Trials.
We have strong links with our neighbouring acute trusts through the local research network and with the other UK ambulance services via national networks. This enables us to hear about the latest research projects and get involved from the early stages.
This trial, led by the University of Warwick, aims to improve the outcome for patients suffering cardiac arrest (when the heart stops beating) outside of the hospital environment. Of the 30,000 people experiencing this catastrophic event each year, no more than 7% survive to hospital discharge.
Although the drug “adrenaline” has been used as part of the standard treatment of cardiac arrest since the 1950’s, there have never been any trials to show whether it is of benefit or not. This trial will look at whether adrenaline, which can be administered during resuscitation, improves a person’s chance of survival to hospital discharge. It had been assumed that by stimulating the heart, adrenaline may improve the chances of successful resuscitation. However, some recent studies have suggested that although adrenaline may indeed help ‘restart’ the heart, the chances of survival in patients given adrenaline may actually be worse. This may be because when adrenaline stimulates the heart it increases the amount of oxygen required by the heart which may, in turn, reduce the amount of oxygen available to the brain.
How the trial will work
The International Liaison Committee on Resuscitation, European Resuscitation Council and Resuscitation Council (UK) which all set the current resuscitation guidelines, have identified the urgent need for a clinical trial to look at whether current adrenaline therapy is safe and effective.
The only way to do this is by a type of research study called a randomised trial comparing adrenaline with a placebo (saline), in which neither the clinician nor the patient is aware of the group into which they have been randomised. Adult patients who suffer cardiac arrest, and where advanced life support is given, will be eligible for the study. Those who are pregnant, suffering from anaphylaxis or where adrenaline has been given prior to ambulance arrival will not be enrolled in the trial.
At a cardiac arrest where adrenaline is indicated, clinicians will be supplied with a pack of trial drugs, which will be used in place of standard adrenaline syringes. Patients will be followed up in hospital and the study investigators will compare what happens to the two groups of patients (those who received adrenaline and those who received placebo).
Members of the public who do not wish to be enrolled in the PARAMEDIC-2 trial can choose to opt-out by requesting a stainless steel bracelet which has the words ‘NO STUDY’ engraved on it.
Local paramedics will be trained to look for these bracelets in the same way they do for other medical ID bands. This means that, in the event that you have a cardiac arrest, you will receive standard treatment which may include adrenaline. This system is used successfully in North America for a number of trials.
You should wear this bracelet for the duration of the trial and will be contacted at the end of the trial to inform you that you no longer need to wear the bracelet.
If you want to request an opt-out bracelet please fill in the form found here. Alternatively please contact the trial team on 02476 151164 or email at email@example.com. We will also use these contact details to advise you when to stop wearing the bracelet.
The trial, funded by the National Institute for Health Research and.co-ordinated by the University of Warwick in collaboration with the University of Surrey, has received Research Ethics Committee approval and Medicines & Healthcare products Regulatory Authority (MHRA) approval. It involves five ambulance Trusts (South Central Ambulance Service, London Ambulance Service, West Midlands Ambulance Service, Welsh Ambulance Service & North East Ambulance Service) and aims to recruit a total of 8,000 patients: the number needed to be sure that any benefit or harm from adrenaline can be detected. The data will be analysed at stages as the trial progresses so that if a difference is detected sooner, the trial can be stopped.
It is usual practice to obtain informed consent from patients to participate in research studies. Inevitably, there are ethical challenges and concerns involved in a trial where patients are unconscious and cannot give their agreement to take part. This has been a concern for researchers working in the pre-hospital setting for some time and has recently been highlighted in the press. It has been suggested that if patients are unable to give consent, either because they are in an emergency situation or are unconscious, they should not be included in a research trial. However, this would severely reduce the opportunities for improving the care of patients suffering conditions such as cardiac arrest. A number of years ago this was debated at the highest level in the UK Government and the European Union. A new law was drawn up that allowed researchers in specific emergency situations to enroll patients in a study without obtaining consent (waiver of consent) so long as consent was obtained as soon as reasonably possible after the patient was able to make a decision. The law regarding informed consent in an emergency situation is set out in Statutory Instrument 2006 No. 2984, The Medicines for Human Use (Clinical Trials) Amendment (No2) Regulation 2006. With appropriate regulatory control, studies of this group of patients are the best way to improve outcomes for those suffering such conditions in future.
The British Heart Foundation Medical Director, Professor Peter Weissberg, said: “It is important to remember that whilst adrenaline is routinely used to treat a cardiac arrest, we don’t actually know whether this is a safe and effective practice. The concern is it could be doing patients more harm than good. The only way to answer this crucially important question is to do a well-designed clinical trial. It is always difficult to conduct a trial in situations where people are too ill to give their consent. But there are well established ethical guidelines for undertaking such studies. What is unacceptable is to continue giving a treatment that could be doing more harm than good. Only by undertaking difficult studies of this kind can we be sure that patients are receiving the highest possible standard of care and have the best chance of a good outcome.”
South Central Ambulance Service will be starting a small pilot study in February, followed by wider implementation in April.
For more information please find a Frequently Asked Questions document and other relevant trial documentation at http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/critical/paramedic2/faqs/
Finally you can contact the SCAS Communications team at Communications@scas.nhs.uk
This project was funded by the National Institute for Health Research Health Technology Assessment programme (project number 12/127/126)
Department of Health Disclaimer:
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Health Technology Assessment Programme NIHR, NHS or the Department of Health.
- Performance in initiating and delivering clinical research July to September 2017
- Performance in initiating and delivering clinical research April to June 2017
- Performance in initiating and delivering clinical research January to March 2017
- Performance in initiating and delivering clinical research October to December 2016
- Performance in initiating and delivering clinical research July to September 2016
- Performance in Initiating and delivering clinical research April to June 2016
- Performance in initiating and delivering clinical research Jan to March 2016
- Performance in initiating and delivering clinical research April to Dec 2015
- Performance in initiating and delivering clinical research April 2015